共 10 条
- [1] Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial[J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (11) : 1517 - 1538Arai, HidenoriYamashita, ShizuyaAraki, EiichiYokote, KoutaroTanigawa, RyoheiSaito, AyumiYamasaki, SayumiSuganami, HidekiIshibashi, Shun
- [2] Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia[J]. ATHEROSCLEROSIS, 2017, 261 : 144 - 152Arai, HidenoriYamashita, ShizuyaYokote, KoutaroAraki, EiichiSuganami, HidekiIshibashi, Shun
- [3] Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (21) : 1923 - 1934Das Pradhan, ArunaGlynn, Robert J.Fruchart, Jean-CharlesMacFadyen, Jean G.Zaharris, Elaine S.Everett, Brendan M.Campbell, Stuart E.Oshima, RyuAmarenco, PierreBlom, Dirk J.Brinton, Eliot A.Eckel, Robert H.Elam, Marshall B.Felicio, Joao S.Ginsberg, Henry N.Goudev, AssenIshibashi, ShunJoseph, JacobKodama, TatsuhikoKoenig, WolfgangLeiter, Lawrence A.Lorenzatti, Alberto J.Mankovsky, BorisMarx, NikolausNordestgaard, Borge G.Pall, DenesRay, Kausik K.Santos, Raul D.Soran, HandreanSusekov, AndreyTendera, MichalYokote, KoutaroPaynter, Nina P.Buring, Julie E.Libby, PeterRidker, Paul M.
- [5] Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial[J]. ATHEROSCLEROSIS, 2016, 249 : 36 - 43Ishibashi, ShunYamashita, ShizuyaArai, HidenoriAraki, EiichiYokote, KoutaroSuganami, HidekiFruchart, Jean-CharlesKodama, Tatsuhiko
- [6] Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association[J]. CIRCULATION, 2011, 123 (20) : 2292 - 2333Miller, MichaelStone, Neil J.Ballantyne, ChristieBittner, VeraCriqui, Michael H.Ginsberg, Henry N.Goldberg, Anne CarolHoward, William JamesJacobson, Marc S.Kris-Etherton, Penny M.Lennie, Terry A.Levi, MosheMazzone, TheodorePennathur, Subramanian
- [7] Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (08) : 3019 - 3027Nichols, Gregory A.Philip, SephyReynolds, KristiGranowitz, Craig B.Fazio, Sergio
- [8] Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine[J]. CLINICAL CHEMISTRY, 2016, 62 (07) : 930 - 946Nordestgaard, Borge G.Langsted, AnneMora, SamiaKolovou, GenovefaBaum, HannsjorgBruckert, EricWatts, Gerald F.Sypniewska, GrazynaWiklund, OlovBoren, JanChapman, M. JohnCobbaert, ChristaDescamps, Olivier S.von Eckardstein, ArnoldKamstrup, Pia R.Pulkki, KariKronenberg, FlorianRemaley, Alan T.Rifai, NaderRos, EmilioLanglois, Michel
- [9] MYOPATHY AND RHABDOMYOLYSIS ASSOCIATED WITH LOVASTATIN-GEMFIBROZIL COMBINATION THERAPY[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (01): : 71 - 75PIERCE, LRWYSOWSKI, DKGROSS, TP
- [10] Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis[J]. PATIENT PREFERENCE AND ADHERENCE, 2013, 7 : 419 - 434Srivastava, KunalArora, AnamikaKataria, AditiCappelleri, Joseph C.Sadosky, AlesiaPeterson, Andrew M.